Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Tougeron

Showing results (121-130 of 235) with videos related to

Pageof 24
Sort By:
JAMA Oncology|June 18, 2025
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical TrialJulien Taïeb, Francesco Giulio Sullo, Aurélie Lecanu, et al.
The Lancet. Oncology|November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trialStefano Kim, Jihane Boustani, Soledad Iseas, et al.
Cancers|April 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, et al.
Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational studyAlexandra Lapeyre-Prost, Geraldine Perkins, Marie Vallee, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 10, 2026
FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinomaDavid Tougeron, Fernando Rivera, Tania Fleitas Kanonnikoff, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 21, 2024
Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR)Thierry Lecomte, David Tougeron, Romain Chautard, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancerMargherita Ambrosini, David Tougeron, Dominik Modest, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2026
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEOEmeric Boisteau, Alice Boilève, David Tougeron, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Folfirinox <i>versus</i> gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score studyNicolas Williet, Angélique Saint, Anne-Laure Pointet, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 14, 2010
HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapyEmilie Fauquembergue, Olivier Toutirais, David Tougeron, et al.
Pageof 24

Showing results (121-130 of 235) with videos related to

Sort By:
Pageof 24
JAMA Oncology|June 18, 2025
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical TrialJulien Taïeb, Francesco Giulio Sullo, Aurélie Lecanu, et al.
The Lancet. Oncology|November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trialStefano Kim, Jihane Boustani, Soledad Iseas, et al.
Cancers|April 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, et al.
Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational studyAlexandra Lapeyre-Prost, Geraldine Perkins, Marie Vallee, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 10, 2026
FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinomaDavid Tougeron, Fernando Rivera, Tania Fleitas Kanonnikoff, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 21, 2024
Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR)Thierry Lecomte, David Tougeron, Romain Chautard, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancerMargherita Ambrosini, David Tougeron, Dominik Modest, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2026
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEOEmeric Boisteau, Alice Boilève, David Tougeron, et al.
Therapeutic Advances in Gastroenterology|October 11, 2019
Folfirinox <i>versus</i> gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score studyNicolas Williet, Angélique Saint, Anne-Laure Pointet, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 14, 2010
HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapyEmilie Fauquembergue, Olivier Toutirais, David Tougeron, et al.
Pageof 24